CLPT SEC Filing News — ClearPoint Neuro, Inc.

Latest SEC filings for ClearPoint Neuro, Inc. (CLPT) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-02.

ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow…
Sector: Healthcare Industry: Medical Devices Market Cap: $276.7M CIK: 1285550
20
Total Filings
0
Bullish Classifications
3
Bearish Classifications
13
Insider Transactions
1
Material Events (8-K)
1
Periodic Reports
Rule-based classifications for CLPT currently lean bearish. Of the 20 filing records displayed, 3 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.
CLPT Filing Activity Snapshot 2026-05-26 — 2026-10-02
Insider Transactions (Form 4)
0 buys vs 3 sells
Net insider selling in this period — insiders sell for many reasons beyond conviction.
Largest Form 144 Filing
$1.10M
BURNETT JOSEPH (Director, CEO and President) · 2026-06-22
61,843 shares · Form 4
Form 144 Notices
5
Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.
Insider Transactions 13 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 13 filings in this group are Form 4s for ClearPoint Neuro, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 13 insider filings shown, the breakdown is 8 compensation award, 3 open-market sale and 2 option exercise. 3 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×8
Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×3
The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Option exercise ×2
The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

Richards Timothy T. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 319 $12.21 $3.9K
Filing: Form 4 (Insider Transaction) Insider: Richards Timothy T. (Director) Shares: 319
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-10-02

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

FLETCHER R JOHN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 993 $12.21 $12.1K
Filing: Form 4 (Insider Transaction) Insider: FLETCHER R JOHN (Director) Shares: 993
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-09-03

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

BURNETT JOSEPH (Director, CEO and President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 12,517 $3.47 $43.4K
M Option exercise derivative · Stock Options (right to buy) 12,517 — —
Filing: Form 4 (Insider Transaction) Insider: BURNETT JOSEPH (Director, CEO and President) Shares: 12,517
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-06

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

FLETCHER R JOHN (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 662 $17.84 $11.8K
Filing: Form 4 (Insider Transaction) Insider: FLETCHER R JOHN (Director) Shares: 662
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-06

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

Richards Timothy T. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 222 $17.84 $4.0K
Filing: Form 4 (Insider Transaction) Insider: Richards Timothy T. (Director) Shares: 222
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-02

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

STIGALL L. JEREMY (Chief Business Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,781 $11.93 $21.2K
Filing: Form 4 (Insider Transaction) Insider: STIGALL L. JEREMY (Chief Business Officer) Shares: 1,781
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-02

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

D'Alessandro Danilo (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,085 $11.93 $12.9K
Filing: Form 4 (Insider Transaction) Insider: D'Alessandro Danilo (Chief Financial Officer) Shares: 1,085
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-07-02

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

BURNETT JOSEPH (Director, CEO and President) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award 1,361 $11.93 $16.2K
Filing: Form 4 (Insider Transaction) Insider: BURNETT JOSEPH (Director, CEO and President) Shares: 1,361
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-07-01

CLPT insider BURNETT JOSEPH (Director, CEO and President) sold 20,000 shares (~$387.6K)

BURNETT JOSEPH, listed as Director, CEO and President at ClearPoint Neuro, Inc., reported an open-market sale of 20,000 CLPT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 20,000 $2.50 $50.0K
S Open-market sale 20,000 $19.38 $387.6K
M Option exercise derivative · Stock Options (right to buy) 20,000 — —
Filing: Form 4 (Insider Transaction) Insider: BURNETT JOSEPH (Director, CEO and President) Shares: 20,000 Est. Value: $387.6K
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-22

CLPT insider BURNETT JOSEPH (Director, CEO and President) sold 61,843 shares (~$1.10M)

BURNETT JOSEPH, listed as Director, CEO and President at ClearPoint Neuro, Inc., reported an open-market sale of 61,843 CLPT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 60,000 $2.50 $150.0K
S Open-market sale 60,000 $17.79 $1.07M
S Open-market sale 1,843 $17.94 $33.1K
M Option exercise derivative · Stock Options (right to buy) 60,000 — —
Filing: Form 4 (Insider Transaction) Insider: BURNETT JOSEPH (Director, CEO and President) Shares: 61,843 Est. Value: $1.10M
View on SEC EDGAR → Open Filing Document →
Form 4 Option exercise Tax / Compensation Filing 2026-06-08

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

Richards Timothy T. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The insider converted options into shares. The exercise price was fixed when the options were granted, so the timing usually tracks an expiry schedule.

Transactions reported on this filing
Code Nature Shares Price Value
M Option exercise 500 $10.00 $5.0K
F Tax withholding on vested shares 376 $13.30 $5.0K
M Option exercise derivative · Stock Options (right to buy) 500 $10.00 $5.0K
Filing: Form 4 (Insider Transaction) Insider: Richards Timothy T. (Director) Shares: 876
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market sale Insider Selling 2026-06-02

CLPT insider Richards Timothy T. (Director) sold 5,415 shares (~$65.9K)

Richards Timothy T., listed as Director at ClearPoint Neuro, Inc., reported an open-market sale of 5,415 CLPT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code Nature Shares Price Value
S Open-market sale 5,415 $12.17 $65.9K
Filing: Form 4 (Insider Transaction) Insider: Richards Timothy T. (Director) Shares: 5,415 Est. Value: $65.9K
View on SEC EDGAR → Open Filing Document →
Form 4 Compensation award Tax / Compensation Filing 2026-05-26

CLPT insider Form 4 filed for equity award, exercise, or tax withholding

FALLON LYNNETTE C (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code Nature Shares Price Value
A Compensation award derivative · Restricted Stock Units 12,820 — —
Filing: Form 4 (Insider Transaction) Insider: FALLON LYNNETTE C (Director)
View on SEC EDGAR → Open Filing Document →
Proposed Insider Sales 5 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. ClearPoint Neuro, Inc. has 5 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-06-29

CLPT Form 144 filed for proposed insider sale by JOSEPH BURNETT (20,000 shares) ~$369.6K

JOSEPH BURNETT filed a Form 144 with the SEC indicating intent to sell CLPT (ClearPoint Neuro, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOSEPH BURNETT Shares: 20,000 Est. Value: $369.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-17

CLPT Form 144 filed for proposed insider sale by JOSEPH M BURNETT TRUST (1,843 shares) ~$24.6K

JOSEPH M BURNETT TRUST filed a Form 144 with the SEC indicating intent to sell CLPT (ClearPoint Neuro, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOSEPH M BURNETT TRUST Shares: 1,843 Est. Value: $24.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-17

CLPT Form 144 filed for proposed insider sale by JOSEPH BURNETT (60,000 shares) ~$800.4K

JOSEPH BURNETT filed a Form 144 with the SEC indicating intent to sell CLPT (ClearPoint Neuro, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: JOSEPH BURNETT Shares: 60,000 Est. Value: $800.4K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-06-01

CLPT Form 144 filed for proposed insider sale by TIMOTHY RICHARDS (5,145 shares) ~$62.6K

TIMOTHY RICHARDS filed a Form 144 with the SEC indicating intent to sell CLPT (ClearPoint Neuro, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: TIMOTHY RICHARDS Shares: 5,145 Est. Value: $62.6K
View on SEC EDGAR → Open Filing Document →
Form 144 Proposed Insider Sale 2026-05-29

CLPT Form 144 filed for proposed insider sale by PASCAL E. GIRIN (66,679 shares) ~$836.5K

PASCAL E. GIRIN filed a Form 144 with the SEC indicating intent to sell CLPT (ClearPoint Neuro, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: PASCAL E. GIRIN Shares: 66,679 Est. Value: $836.5K
View on SEC EDGAR → Open Filing Document →
Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for ClearPoint Neuro, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-03

CLPT filed 8-K — material company event

ClearPoint Neuro, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)
View on SEC EDGAR → Open Filing Document →
Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for ClearPoint Neuro, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-03

CLPT filed Quarterly Report (10-Q)

ClearPoint Neuro, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)
View on SEC EDGAR → Open Filing Document →

How we classify ClearPoint Neuro, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on CLPT. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — CLPT SEC Filings

More Tools for CLPT

CLPT Full Stock Analysis CLPT Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper CLPT analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the CLPT stock analysis page.

CLPT Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer